A Phase 1 interventional study of HE3286 in Insulin Resistance, sponsored by Harbor Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-09.
Sponsored by Harbor Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 150 under way, 2 of them phase 3. Insulin Resistance · United States.
Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 869th largest by enrollment of the 936 interventional ones that give a count, is one of 69 that started in 2009, is one of 116 in phase 1, and was the 364th registered.
2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.
Browse Insulin Resistance studies →117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–100
HealthPartners Institute · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
University of Colorado, Denver · Sites in United States
Ages 14–19
St. Louis University · Sites in United States
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 162 · Phase 3 45 · Phase 4 99
First in 1976; this study’s year is marked. 69 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 37 across the 936 interventional studies, 48 across the 174 observational. Of the 871 that completed or were terminated, 311 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 1,118 have an industry lead sponsor. The 10 most frequent:
Harbor Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.
Harbor Therapeutics has 2 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
52 of the studies in Insulin Resistance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03947697University of Texas, El PasoImproving Glycemic Control With Electrical Stimulation | 2026-11-25 |
| NCT05958368Pennington Biomedical Research CenterAssessing the Value of Avocados on Glycemic Control in Type 2 Diabetes | 2026-11-30 |
| NCT05441982Virginia Polytechnic Institute and State UniversitySaccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes | 2026-11-30 |
| NCT03318094Vanderbilt University Medical CenterRole of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity | 2026-11-30 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,118 studies in Insulin Resistance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.
Hollis-Eden Pharmaceuticals, Inc. is developing a new class of therapeutics for the treatment of Type 2 diabetes mellitus (T2DM). The investigational drug, HE3286, is a synthetic analog of a naturally occurring hormone with a potentially new mechanism of action that may improve the current therapeutic options available to a T2DM patient.
The glucose clamp is the gold standard for measurement of insulin sensitivity. Given the observed activity of HE3286 in reducing insulin resistance in both impaired glucose intolerant subjects and type 2 diabetic patients, it is necessary to evaluate the physiological site of action (i.e. liver vs. skeletal muscle) of HE3286 in order to further understand the mechanism of action and to design future clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HE3286 20 mg (10 mg BID)
Drug: HE3286
HE3286 20 mg (10 mg BID) for 28 days
Also known as: TRIOLEX
Safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects
Time frame: Study duration and 1-month follow-up
Activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.
Time frame: Study period (28-days)
The record gives a start of Sep 2009, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bezisterim
Harbor Therapeutics